ICD-10-CM Billable Code

M08.259

Juvenile rheumatoid arthritis with systemic onset, unspecified hip

Clinical Classification Guidelines

Medical Intelligence & Overview

Juvenile rheumatoid arthritis (JRA), also known as juvenile idiopathic arthritis (JIA), is a type of arthritis that affects children and adolescents. The specific subtype characterized by systemic symptoms with involvement of the hip (ICD-10 code M08.259) manifests as a widespread inflammatory condition that impacts multiple joints and other organs. This form of arthritis can significantly influence a child's growth, development, and quality of life, necessitating a comprehensive understanding of its features.

Causes & Symptoms

Clinical Causes: The exact cause is unknown, but it involves autoimmune processes where the immune system mistakenly targets healthy tissues. Genetic factors may increase susceptibility, with certain genes related to immune regulation playing a role. Environmental triggers such as infections or other exposures may contribute to the onset or flare-ups.

Key Symptoms: Persistent fever that may spike in the evenings Rash, often fleeting and salmon-pink in appearance Swelling and pain in joints, notably the hips, as well as knees, ankles, and wrists S swollen lymph nodes, hepatosplenomegaly (enlarged liver and spleen) Fatigue and malaise (general feeling of discomfort or illness) Loss of appetite and weight loss Muscle pain and stiffness Potential involvement of other organs, leading to symptoms like sore throat, chest pain, or inflammation of the heart and lungs

Diagnostic & Treatment

Diagnosis Path: The diagnosis involves a combination of clinical evaluation and laboratory investigations: - Medical history review focusing on systemic symptoms and joint involvement - Physical examination assessing joint swelling, redness, and range of motion - Blood tests including complete blood count (CBC), inflammation markers (ESR, CRP), and autoantibodies - Imaging studies such as X-rays or MRI scans of affected joints to evaluate joint damage and inflammation - Exclusion of other conditions that may mimic juvenile rheumatoid arthritis A multidisciplinary approach may be necessary to confirm systemic involvement and exclude other diseases.

Treatment Protocols: While treatment strategies aim to control symptoms and prevent joint damage, they are tailored to individual cases: - Nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain - Corticosteroids for severe cases or systemic symptoms - Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate to slow disease progression - Biologic agents targeting specific immune pathways, used in refractory cases - Physical therapy to maintain joint function and muscle strength - Regular monitoring to assess disease activity and treatment response - Supportive care including pain management, nutritional support, and psychosocial assistance. It is essential for affected children to have ongoing medical supervision to manage the condition effectively.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M08.259 a billable ICD-10 code?
Yes, M08.259 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M08.259?
Clinical documentation must specify the nature of Juvenile rheumatoid arthritis with systemic onset, unspecified hip and any associated comorbidities for accurate reporting.

Cite this Clinical Reference